Published in Cancer Weekly, September 24th, 2002
GRN163 acts by inhibiting telomerase, an enzyme that facilitates indefinite cell division, an important factor in the development of cancers. This new agreement follows the successful process development collaboration between Geron and RPI, previously announced in December of 2001 for the scale up and optimization of the manufacturing process.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.